Amundi Asset Management US’s Regeneron Pharmaceuticals REGN Stock Holding History

Amundi Asset Management US’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	$78.4M	Sell	165,712 -37,328	-18%	-$18.2M	0.06%	320
2020 Q4	$98.1M	Sell	203,040 -17,695	-8%	-$9.55M	0.08%	261
2020 Q3	$124M	Buy	220,735 +7,077	+3%	+$4.29M	0.13%	162
2020 Q2	$133M	Buy	213,658 +86,736	+68%	+$49.2M	0.16%	129
2020 Q1	$62M	Sell	126,922 -49,540	-28%	-$20.4M	0.11%	185
2019 Q4	$66.3M	Buy	176,462 +51,304	+41%	+$17.3M	0.08%	256
2019 Q3	$34.7M	Buy	125,158 +31,000	+33%	+$9.17M	0.05%	365
2019 Q2	$29.5M	Sell	94,158 -134,803	-59%	-$44.9M	0.02%	472
2019 Q1	$94M	Sell	228,961 -1,726	-0.7%	-$711K	0.13%	161
2018 Q4	$86.2K	Buy	230,687 +74,827	+48%	+$27.4M	0.08%	174
2018 Q3	$63M	Buy	155,860 +106,563	+216%	+$40.6M	0.08%	240
2018 Q2	$17M	Sell	49,297 -35,768	-42%	-$11.2M	0.02%	565
2018 Q1	$29.3M	Buy	85,065 +14,837	+21%	+$5.16M	0.05%	383
2017 Q4	$26.4M	Buy	+70,228	New	+$28.4M	0.04%	397
2016 Q1	–	Sell	-391	Closed	-$212K	–	572
2015 Q4	$212K	Buy	+391	New	+$212K	﹤0.01%	536
2015 Q2	–	Sell	-482	Closed	-$218K	–	642
2015 Q1	$218K	Buy	+482	New	+$204K	﹤0.01%	594

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Amundi Asset Management US's REGN Position: Q1 2021 in Review

Amundi Asset Management US reduced its Regeneron Pharmaceuticals (REGN) stake by 18% in Q1 2021, selling an estimated $18.2M and leaving 165,712 shares worth $78.4M. The position accounts for 0.06% of the portfolio, ranked #320.

Amundi Asset Management US first reported a position in REGN in Q1 2015 and has held it in 16 quarters since. The position peaked at $133M in Q2 2020. 925 funds tracked by Wall St. Rank hold REGN as of Q1 2021.

Amundi Asset Management US held 165,712 shares of Regeneron Pharmaceuticals worth $78.4M as of Q1 2021.
Amundi Asset Management US sold 37,328 Regeneron Pharmaceuticals shares in Q1 2021, an estimated $18.2M.
Regeneron Pharmaceuticals made up 0.06% of Amundi Asset Management US's portfolio in Q1 2021, its #320 holding.
Amundi Asset Management US first reported a position in Regeneron Pharmaceuticals in Q1 2015 and has held it in 16 quarters since.
Amundi Asset Management US's Regeneron Pharmaceuticals position peaked at $133M in Q2 2020.
925 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2021.

Based on Amundi Asset Management US's 13F filing for Q1 2021, filed 17 May 2021.